LENZ Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted from Q2 2021 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
LENZ Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q2 2021 to Q2 2024.
  • LENZ Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending June 30, 2024 was 25.6M shares, a 1209% increase year-over-year.
  • LENZ Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 57M shares, a 3.9% increase from 2022.
  • LENZ Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 54.9M shares, a 89.7% increase from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 25.6M +23.7M +1209% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 4.72M +2.77M +142% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 57M +2.14M +3.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 57.3M +2.05M +3.72% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 1.96M -52.6M -96.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 1.95M -52.1M -96.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 54.9M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 55.2M +2.44M +4.62% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 54.6M +49.5M +973% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 54M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q3 2021 52.8M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 5.09M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.